Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Uso de péptido intestinal vasoactivo (VIP) como marcador de pronóstico de enfermedades autoinmunes

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20150514001
Publicado:
18/08/2015
Caducidad:
17/08/2016
Resumen:
Un equipo de investigación español, en colaboración con un instituto de investigación biomédica de un hospital, ha descubierto un biomarcador que identifica las fases tempranas de la artritis reumatoide y espondiloartritis. El grupo de investigación ha descubierto que tener bajos niveles de VIP en suero es un biomarcador del peor curso clínico. Esto mejora el valor predictivo de anticuerpos contra proteínas citruniladas (ACPA) y el tratamiento relacionado. Se buscan compañías biofarmacéuticas con el fin de establecer acuerdos de licencia o joint venture.

Details

Tittle:
Use of VIP (Vasoactive intestinal peptide ) as a prognostic marker of autoimmune diseases
Summary:
A Spanish research group in collaboration with a hospital biomedical research institute, have identified that having low VIP serum levels is a biomarker of worse clinical course and higher requirements of treatment in patients with early Rheumatoid arthritis and Spondyloarthritis. This improves the predictive value of ACPA (anti-citrullinated protein antibodies), and the related treatment.
They are looking for biopharmaceutical companies for licensing or joint venture agreement.
Description:

The Spanish research group in collaboration with a hospital biomedical research institute have discovered a biomarker that identifies early stages of RA and Spa,
Rheumatoid arthritis (RA) and Spondyloarthritis (Spa) are autoimmune disorders that can lead to severe disability and increased mortality. Early intensive immunomodulatory treatment is the best approach to slow progression and change long-term outcome. However, it is important to detect those patients who are destined to have a more benign disease to avoid over-treating them. Probably the only validated prognostic factor in RA is anti-citrullinated protein antibodies (ACPA). There are no validated biomarkers for Spa and other autoimmune disorders.
The research group has described that having low VIP serum levels is a biomarker of worse clinical course and higher requirements of treatment in patients with early RA and Spa the relevance of this new biomarker is that it improves the predictive value of ACPA since detect ACPA negative patients at risk of poor evolution and those with both biomarkers exhibited higher requirements of treatment.
VIP has been involved in the differentiation of Th lymphocytes decreasing the production of proinflammatory mediators and administration of exogenous VIP ameliorates arthritis in murine models. It is likely that those patients who are unable to up-regulate their VIP levels when they develop RA, show a worse clinical course.
They are looking for biopharmaceutical companies interested in licensing the technology of for joint venture agreement. These partnership are the most suitable for them as their developments cannot go further and need a partner to jointly continue with it, or interested in license in the development to introduce it into their portfolio and develop it.
Advantages and Innovations:
The main advantage is that by the administration of this product, it could be possible to diagnose patients to a more intense treatment at first stages. This implies a clear save of costs, as in some of the patients early diagnosed an overtreatment can be avoided.
Prevents progression of RA and Spa, as they are identified in early stages.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Spanish patente application and PCT application

Partner sought

Type and Role of Partner Sought:
Biopharmaceutical company that want to quickly expand the patent portfolio, related with diagnostics on autoimmune diseases.
The research group could develop further innovations for the biopharmaceutical company if the agreement is as joint venture.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Italian
Spanish

Keywords

Technology Keywords:
06002001 Bioquímica / biofísica
06001005 Diagnósticos, diagnosis